US Patent 7674904 Synthesis of R-N-methylnaltrexone
Patent 7674904 was granted and assigned to Progenics Pharmaceuticals on March, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 26 Jun, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 30 Oct, 2023
Golden AI
Edits made to:
Article (+201 characters)
Article
Patent abstract
This invention relates to stereoselective synthesis of R-MNTX and intermediates thereof, pharmaceutical preparations comprising R-MNTX or intermediates thereof and methods for their use.
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07674904 Synthesis of R-N-methylnaltrexone US Patent 7674904 Synthesis of R-N-methylnaltrexone
Infobox
Patent Number
0767490400
Patent Number
767490400
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
076749040
Date of Patent
March 9, 2010
0Patent Application Number
114413950
Date Filed
May 25, 2006
0Official Website
Patent Primary Examiner
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
076749040
Date of Patent
March 9, 2010
0Patent Application Number
114413950
Date Filed
May 25, 2006
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 4 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07674904 Synthesis of R-N-methylnaltrexone
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07674904
Date of patent
March 9, 2010
Patent application number
11441395
Date Filed
May 25, 2006
Patent primary examiner
Find more entities like US Patent 7674904 Synthesis of R-N-methylnaltrexone
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.